Repurposing Preclinical Models for Mechanistic Insights & Target Validation to Uncover the Next Generation of Complement Inhibitors
Time: 10:00 am
day: Conference Day Two
Details:
- Reframing the primary value of preclinical models to focus on the validation of specific aspects of a drugs mechanism of action
- Deep-diving into an example to show how humanized complement models can show the effective inhibition of C3 and C3-driven Kidney model
- Confirming target engagement, particularly for clinically validated targets where the functional outcome is more directly anticipated
